论文部分内容阅读
目的 :对比观察 NP和 CAP方案治疗晚期非小细胞肺癌的疗效、毒副作用。方法 :收集晚期非小细胞肺癌 94例 ,以随机、对照的原则分为 NP方案化疗组和 CAP方案化疗组 ,对比观察两者间疗效、毒副作用、缓解期和生存期的差异。结果 :NP方案化疗组 46例患者的有效率 39.1%与 CAP方案化疗组 48例患者的有效率35 .4%间无显著性差异 (P>0 .0 5 ) ;但 NP方案化疗组 5月的中位缓解期和 9月的中位生存期较 CAP方案化疗组的 4月和 7月均有所延长 ;除具有一般化疗药物所共有的毒副作用外 ,NP方案对骨髓造血组织的抑制 ,特别是对粒细胞系和巨核细胞系较 CAP方案为重 ,另外其周围神经炎和静脉炎的发生率也较高。结论 :NP和 CAP方案都是治疗晚期 NSCL C的较为有效的化疗方案 ,但 NP方案化疗组的缓解期和生存期较长 ,优于 CAP方案化疗组 ,毒副作用均可耐受 ,如辅以 G- CSF等支持对症措施 ,NP方案有更好的临床应用价值
Objective: To compare the efficacy and side effects of NP and CAP regimens in the treatment of advanced non-small cell lung cancer. Methods: 94 cases of advanced non-small cell lung cancer were randomly divided into two groups: NP chemotherapy group and CAP chemotherapy group. The curative effect, toxic and side effects, remission period and survival time were compared. RESULTS: There was no significant difference (39.1%) in the efficacy rate of 39.1% in the NP chemotherapy group and 48.5% in the CAP chemotherapy group (P>0.05); however, the NP chemotherapy group was in May. The median remission period in September and the median survival period in September were both longer in April and July than in the CAP regimen chemotherapy group. In addition to the toxic and side effects common to general chemotherapy drugs, the NP regimen inhibited bone marrow hematopoietic tissue. In particular, granulocytic and megakaryocytic cell lines are more important than CAP regimens, and the incidence of peripheral neuritis and phlebitis is also high. Conclusion: Both NP and CAP regimens are effective chemotherapies for the treatment of advanced NSCL C. However, the NP regimen chemotherapy group has a longer remission period and survival time than the CAP regimen chemotherapy group. The toxic and side effects can be tolerated, such as supplementation. G-CSF and other support symptomatic measures, NP program has better clinical application value